| Literature DB >> 26753565 |
Fesih Aktar1, Recep Tekin2, Mehmet Selçuk Bektaş3, Ali Güneş4, Muhammet Köşker5, Sabahattin Ertuğrul6, Kamil Yılmaz7, Kamuran Karaman8, Hasan Balık9, İlyas Yolbaş10.
Abstract
BACKGROUND: As a multisystem infectious disease, there is an inflammation, which causes increase in acute phase reactants in brucellosis. The mean platelet volume (MPV), platelet distribution width (PDW), red cell distribution width (RDW), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been identified as markers of inflammation. The present study aimed to evaluate diagnostic values of these biomarkers in brucella arthritis (BA).Entities:
Mesh:
Substances:
Year: 2016 PMID: 26753565 PMCID: PMC4709903 DOI: 10.1186/s13052-016-0211-5
Source DB: PubMed Journal: Ital J Pediatr ISSN: 1720-8424 Impact factor: 2.638
Demographic and clinical characteristics and treatment modalities in patients with Brucella arhtritis
| Clinical features | Mean ± SD, median range or number (%) (n:64) |
|---|---|
| Mean age (month) | 92.3 ± 41.2 |
| Gender | |
| Male | 34 (53.1) |
| Female | 30 (46.9) |
| Duration of hospitalization (day) | 6 (2–76) |
| Symptoms and clinical findings | |
| Arthralgia | 64 (100) |
| Joint pain | 61 (95.3) |
| Fever | 55 (85.9) |
| Myalgia | 49 (76.6) |
| Anorexia | 46 (71.9) |
| Weakness | 40 (62.5) |
| Shivering | 39 (60.9) |
| Restriction of movement | 36 (56.2) |
| Diaphoresis | 33 (51.6) |
| Swelling | 22 (34.3) |
| Increase temperature on joint | 22 (34.3) |
| Joint redness | 22 (34.3) |
| Headache | 20 (31.3) |
| Abdominal pain | 14 (21.9) |
| Joint effusion | 13 (20.3) |
| Chest pain | 11 (17.2) |
| Neck pain | 2 (3.1) |
| Joint involvement | |
| Ankle | 34 (53.1) |
| Knee | 30 (46.9) |
| Laboratory findings | |
| Erythrocyte sedimentation rate (mm/h) | 40.9 ± 20.4 |
| C-reactive protein (mg/L) | 28.1 ± 22.4 |
| Brucella hemagglutination test | |
| 160 | 10 (15.8) |
| 320 | 25 (39.1) |
| ≥640 | 29 (45.3) |
| Positive culture | |
| Blood | 4 (6.3) |
| Joint puncture | 4 (6.3) |
| Blood + Joint puncture | 5 (7.9) |
| Treatment | |
| Rifampicin + Tetracycline + Streptomycin | 13 (20.3) |
| Rifampicin + Tetracycline + Gentamicin | 14 (21.8) |
| Rifampicin + TMP-SMX + Gentamicin | 37 (57.8) |
TMP-SMX trimethoprim-sulfamethoxazole, SD standard deviation
Laboratory findings of the study and control groups
| Parameters | Study group mean ± SD or median range | Control group mean ± SD or median range |
|
|---|---|---|---|
| WBC (K/μL) | 10.0 ± 4.2 | 8.25 ± 1.7 | 0.040 |
| Neutrophil (103/μL) | 7.10 (1.70-16.5) | 3.98 (2.20-9.12) | <0.001 |
| Lymphocyte (103/μL) | 1.60 (0.60-7.0) | 2.92 (0.73-4.95) | <0.001 |
| Platelet count (K/μL) | 282 ± 144 | 314 ± 65.7 | <0.001 |
| PDW,% | 38,1 ± 3.0 | 23.0 ± 3.9 | <0.001 |
| RDW,% | 16.2 ± 1.4 | 9.4 ± 1.8 | <0.001 |
| MPV (fl) | 8.2 (6.3-11) | 7.3 (5.7-12.3) | 0.026 |
| NLR | 4.1 (1–13) | 1.4 (0.6-10.8) | <0.001 |
| PLR | 154 (9.3-497) | 106 (50–525) | <0.001 |
WBC white blood cell, PDW platelet distribution width, RDW red cell distribution width, MPV mean platelet volume, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, SD standart deviation
Fig. 1The relationship between mean platelet volume and neutrophil to lymphocyte ratio